期刊文献+

多发性骨髓瘤的治疗进展 被引量:6

下载PDF
导出
摘要 多发性骨髓瘤(multiple myeloma,MM)呈常见于中老年人群的恶性单克隆性浆细胞疾病,约占血液系统恶性肿瘤的10%,居血液系统恶性肿瘤第2位,患者生存期从数月到数年不等。传统上治疗MM的主要方法是化疗和造血干细胞移植,
出处 《实用肿瘤杂志》 CAS 2013年第4期351-355,共5页 Journal of Practical Oncology
  • 相关文献

参考文献3

二级参考文献19

  • 1Durie BG,Salmon SE.A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features,response to treatment and surrival[J].Cancer,1975,36(3):842.
  • 2Blade J,Samson D,Reece D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haematopoietic stem cell transplantation[J].Br J Haematol,1998,102(5):1115.
  • 3Dancey J,Eisenhauer EA.Current perspectives on cam ptothecin in cancer treatment[J].BrJ Cancer,1996,74:327.
  • 4Dankbarb,Padro T,Leor,et al.Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromalcell interactions in multiple myeloma[J].Blood,2000,95:2630.
  • 5Davies FE,Rollinson SJ,Rawstron AC,et al.High producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression free survival after treatment[J].J Clin Oncol,2000,18:2843.
  • 6陆紫敏,张全,祖亚钧,孙向华,梁萍.多发性骨髓瘤患者肿瘤坏死因子α水平及其基因启动子多态性的研究[J].中华内科杂志,2007,46(9):767-768. 被引量:2
  • 7Cavo M, Baccarani M. The changing landscape of myeloma therapy. N Engl J Med 2006;354:1076-8.
  • 8Kumar SK, Raikumar S:; Dispenzieri A, et al. Improved survfval in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
  • 9Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Frangais du My6lome. N Engl J Med 1996;335:91-7.
  • 10Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007;13:183-96.

共引文献24

同被引文献84

  • 1臧洪敏,陈君长,刘亦恒,刘润侠,王坤正.补肾活血方对大鼠成骨细胞增殖、分化及矿化的影响[J].中国中西医结合杂志,2005,25(12):1112-1114. 被引量:16
  • 2史春雷,王玲,尹刚,袁成录.唑来膦酸联合化疗对多发性骨髓瘤病人骨痛的治疗效果[J].齐鲁医学杂志,2006,21(1):41-42. 被引量:4
  • 3蒋铁斌,李昕,刘竞,肖广芬.唑来膦酸钠联合化疗治疗多发性骨髓瘤疗效观察[J].广东医学,2007,28(3):443-443. 被引量:2
  • 4黄春临,朱晓新.中药药理与临床手册[M].北京:人民卫生出版社,2006:426-694.
  • 5宋燕萍.骨髓瘤骨病发病机制及诊治的研究进展.国际输血及血液学杂志,2008,31(2):174-177.
  • 6张之南,沈悌.血液病诊断及疗效标准[M].北京:科学出版社,2008.103-122,131-134,172-176.
  • 7陈令松.早期采集干细胞而于晚期移植作为多发性骨髓瘤的一种有效治疗策略[J].国外医学.输血及血液学分册,2009,18(6):126-127.
  • 8Kim HJ,Yoon SS,Lee DS,et al.Sequential vincristine,adriamycin,dexamethasone(VAD)followed by bortezomib,thalidomide,dexamethasone(VTD)as induction,followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma:Results of a phase II trial [J].Ann Hematol,2012,91(2):249-259.
  • 9Green JR,Guenther A.The backbone of progress-preclinical studies and innovations with zoledronic acid [J].Crit Rev Oncol Hematol,2011,77(Suppl 1):S3-S12.
  • 10Morgan G,Child J,Gregory W,et al.Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma(MRC Myeloma IX):Secondary outcomes from a randomized controlled trial[J].Lancet Oncol,2011,12(8):743-752.

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部